lymphoproliferative disorders
Showing 1 - 25 of 42
Metastatic Cancer, Solid Tumor Cancer, Lymphoproliferative Disorders Trial in Boulder (Written Exposure Therapy)
Recruiting
- Metastatic Cancer
- +5 more
- Written Exposure Therapy
-
Boulder, ColoradoUniversity of Colorado Boulder
Sep 13, 2023
Immune System Diseases, Autoimmune Diseases, Inflammation Trial (observational cohort study)
Not yet recruiting
- Immune System Diseases
- +15 more
- observational cohort study
- (no location specified)
Jul 23, 2023
Breast Cancer, Stage 0, Colorectal Cancer Stage I, Head Neck Cancer Stage I Trial (CaRE@Home intervention)
Not yet recruiting
- Breast Cancer, Stage 0
- +11 more
- CaRE@Home intervention
- (no location specified)
Jun 9, 2023
Liquid Biopsy to Enable Diagnostics and Monitoring for
Recruiting
- Lymphoproliferative Disorders
- Lymphoproliferative Disorder Following Transplantation
- Liquid biopsy
-
Basel, Switzerland
- +5 more
Mar 24, 2023
Lymphoproliferative Disorders, Premalignant, Monoclonal B-Cell Lymphocytosis Trial (No intervention)
Not yet recruiting
- Lymphoproliferative Disorders
- +3 more
- No intervention
- (no location specified)
Jan 30, 2023
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders Trial in Bethesda,
Recruiting
- Lymphoproliferative Disorders
- +4 more
- Immunosuppression Only Conditioning
- +3 more
-
Bethesda, Maryland
- +1 more
Jan 25, 2023
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases Trial run by the NCI (drug, radiation,
Recruiting
- Lymphoproliferative Disorders
- +4 more
- Busulfan test dose
- +8 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)
Recruiting
- Lymphoma
- +7 more
- ATLCAR.CD30 cells
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD), EBV+
Recruiting
- Epstein-Barr Virus (EBV)-Associated Diseases
- +13 more
- Tabelecleucel
-
Los Angeles, California
- +39 more
Nov 9, 2022
T-Cell Tumor, Lymphoproliferative Disorders Trial in Ann Arbor (Pacritinib)
Not yet recruiting
- T-Cell Neoplasm
- Lymphoproliferative Disorders
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Oct 6, 2022
Pathogenesis of Hematologic Malignancies
Enrolling by invitation
- Acute Leukemia
- +3 more
- blood draw, bone marrow procedure, or tissue biopsy
-
Portland, OregonOHSU Knight Cancer Institute
Sep 9, 2022
Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases Trial in Bethesda,
Recruiting
- Primary T-cell Immunodeficiency Disorders
- +4 more
- Immunosuppression Only Conditioning -Closed with amendment L
- +4 more
-
Bethesda, Maryland
- +1 more
Jul 26, 2022
Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome Trial in Cleveland
Not yet recruiting
- Allogeneic Stem Cell Transplant Candidate
- +4 more
- Cellular therapy product
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Jul 1, 2022
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)
Not yet recruiting
- Lymphoma, Mantle-Cell
- +7 more
- Zilovertamab
- +2 more
- (no location specified)
Jun 21, 2022
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications,
Recruiting
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- +4 more
- tabelecleucel
-
Duarte, California
- +70 more
Jun 23, 2022
Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)
Active, not recruiting
- Multiple Myeloma
- +19 more
- CYNK-001
-
Denver, Colorado
- +8 more
May 24, 2022
Myeloproliferative Disorders, Lymphoproliferative Disorders Trial in Pierre-Bénite (Blood collection for the evaluation of the
Not yet recruiting
- Myeloproliferative Disorders
- Lymphoproliferative Disorders
- Blood collection for the evaluation of the anti-drugs sensitivity
-
Pierre-Bénite, France
- +1 more
Mar 2, 2022
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 cells)
Active, not recruiting
- Hodgkin Disease
- +8 more
- ATLCAR.CD30 cells
-
Chapel Hill, North Carolina
- +1 more
Mar 2, 2022
EBV-Related Hodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Non-Hodgkin's Lymphoma Trial in Houston (Dose Level 1A:
Not yet recruiting
- EBV-Related Hodgkin Lymphoma
- +2 more
- Dose Level 1A: 2 x 10^7 cells/m2
- +4 more
-
Houston, Texas
- +1 more
Feb 7, 2022
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma Trial (tabelecleucel)
Available
- Epstein-Barr Virus (EBV) Infections
- +11 more
- tabelecleucel
- (no location specified)
Feb 15, 2022
Lymphoma, Lymphoma, Mantle-Cell, Tumors by Histologic Type Trial (IM19 CAR-T cells, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Lymphoma
- +4 more
- IM19 CAR-T cells
- +2 more
- (no location specified)
Nov 30, 2021
NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma Trial in Houston (EBVST Cells, Nivolumab)
Completed
- NonHodgkin Lymphoma
- +6 more
- EBVST Cells
- Nivolumab
-
Houston, Texas
- +1 more
Jul 19, 2021